Clinical Trial Update: Trastuzumab Deruxtecan (T-DXd) With Pyrotinib in First-line HER2-positive Unresectable or Metastatic Breast Cancer Trial [Phase 4]

View source ↗

Summary

Phase 4 trial update evaluating trastuzumab deruxtecan in combination with pyrotinib for first-line HER2-positive unresectable or metastatic breast cancer; not …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Conditions: Breast Cancer | Phase 4 | Status: NOT_YET_RECRUITING